Indeed, large randomized controlled trials evaluating RAAS inhibition in congestive HF (TRACE, Val-HeFT, CHARM) demonstrated that treatment with an ACE-I or ARB significantly reduced the risk of new-onset AF [146]. Here, ACE is linked to atrial fibrillation.